Radezolid, a next-generation oxazolidinone
, represents a novel class of antimicrobials to target acne and demonstrated strong in vitro activity regardless of the resistance profile of the pathogen, where other agents were not as active against the resistant pathogens.
Tedizolid is a novel oxazolidinone
with high potential of action that is approximately four times more potent than linezolid.
Sutezolid is an oxazolidinone
, the same class of drug as linezolid, which is also under investigation by the TB Alliance in early Phase II and Phase III clinical trials.
Linezolid, an oxazolidinone
antibacterial agent, has proven to be effective in the treatment of the glycopeptideresistant Enterococcus, as well as methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae in children, and was used to treat the infected patients in this study.
In the later stage, the absorbance of oxazolidinone
groups (1758 [cm.
Linezolid is the first antibiotic introduced from the oxazolidinone
Stability of linezolid activity in an era of mobile oxazolidinone
resistance determinants: results from the 2009 Zyvox(R) Annual Appraisal of Potency and Spectrum program.
AZD5847 is a member of the oxazolidinone
class, which includes drugs such as linezolid, while TBA-354 is a nitroimidazole, which includes pretomanid and Deltyba (delamanid).
SIVEXTRO is a novel oxazolidinone
with in vitro activity against clinically significant susceptible Gram-positive pathogens including MRSA and is now approved in both an intravenous (I.
MicuRx, which has previously raised USD12m in Series A venture funds from Morningside and Devon Park Bioventures, added it will use the fresh financing to support the US development of its oral oxazolidinone
antibiotic MRX-I, which targets infections due to multi-drug resistant Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE).
1 Linezolid was the first oxazolidinone
to be developed and approved for clinical use in the USA in April 2000, and it is active against drug resistant gram-positive bacteria.
Cadazolid is in the oxazolidinone
class of antibiotics.